Portfolio company
Autolus
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Autolus develops programmed T-cell therapies for patients with cancer and autoimmune diseases, including an approved treatment for adult B-cell acute lymphoblastic leukaemia.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
Allogene Therapeutics
The company develops off-the-shelf allogeneic CAR T-cell therapies for patients with blood cancers, solid tumours and autoimmune diseases.
Arcellx
This biotechnology company develops cell therapies to treat patients with cancer and autoimmune diseases.
Artiva Biotherapeutics
The company develops allogeneic natural killer cell therapies for patients with autoimmune diseases and cancer.
T-CURX
This biotech company develops non-viral CAR-T cell therapies to treat patients with leukaemia, lymphoma and solid tumours.
Orca Bio
This company develops high-precision allogeneic cell therapies to treat patients with blood cancers and autoimmune diseases by replacing diseased immune systems with donor cells.
ArsenalBio
The company develops programmable T cell therapies for patients with solid tumours and autoimmune diseases.
curocell
This company develops chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory blood cancers such as diffuse large B-cell lymphoma.